KLK3 and posterior cortical atrophy: PSA testing is recognized as a primary tool for monitoring PCa progression, especially in active surveillance for low- to intermediate-risk patients, according to several guidelines, including those from the American Urological Association (DUA) and the National Comprehensive Cancer Network (NCCN).